Detection of Biomarkers for Improved Prognosis of Hodgkin’s Lymphoma
Research type
Research Study
Full title
Identification of Biomarkers for Improved Prognosis of Hodgkin’s Lymphoma: A Pilot Metabolomics Investigation
IRAS ID
152029
Contact name
Martin Grootveld
Contact email
Sponsor organisation
De Montfort University
Duration of Study in the UK
1 years, 2 months, 28 days
Research summary
In this investigation the applicants shall employ ‘state-of-the-art’ analytical techniques with the ability to simultaneously monitor hundreds of molecules in human body fluid samples, in order to seek and identify those which serve as reliable indicators of the future course and outcome of patients with Hodgkin’s Lymphoma (HL) disease. We shall also use this information to monitor the response of patients to treatment. Subsequently, this information will be employed to enhance our understanding of the HL disease process (through the recognition and measurement of ‘patterns’ of these molecules which are characteristic of the disease process). Such valuable information may also facilitate the design of new treatment regimens for this devastating clinical condition. Prognostic screening developments arising from this pilot study could, at least in principle, be implemented in clinical settings within 2-3 years after its completion.
The development and validation of methods and techniques for the recognition of ‘patterns’ of blood plasma and urinary biomolecules, which will inform us about the progress, severity and classifiable prognostic outcome of HL patients, together with their response to treatment, will offer major benefits to those afflicted; it will also provide information which may potentially be employed for the future development of novel, ‘hand-held’ biochemical sensors for the diagnosis and monitoring of the prognostic status of HL.
REC name
Yorkshire & The Humber - Leeds West Research Ethics Committee
REC reference
14/YH/1295
Date of REC Opinion
31 Dec 2014
REC opinion
Further Information Favourable Opinion